Institution
University of Queensland
Education•Brisbane, Queensland, Australia•
About: University of Queensland is a education organization based out in Brisbane, Queensland, Australia. It is known for research contribution in the topics: Population & Poison control. The organization has 51138 authors who have published 155721 publications receiving 5717659 citations. The organization is also known as: UQ & The University of Queensland.
Papers published on a yearly basis
Papers
More filters
University of Sydney1, Alfred Hospital2, German Cancer Research Center3, University of Queensland4, Freeman Hospital5, University of Oslo6, University of Bordeaux7, French Institute of Health and Medical Research8, Sheba Medical Center9, University of Kiel10, University of Zurich11, Novartis12, Macquarie University13, University of Pittsburgh14
TL;DR: Adjuvant use of combination therapy with dabrafenib plus trametinib resulted in a significantly lower risk of recurrence in patients with stage III melanoma with BRAF V600E or V600K mutations than the adjuvantUse of placebo and was not associated with new toxic effects.
Abstract: BackgroundCombination therapy with the BRAF inhibitor dabrafenib plus the MEK inhibitor trametinib improved survival in patients with advanced melanoma with BRAF V600 mutations. We sought to determine whether adjuvant dabrafenib plus trametinib would improve outcomes in patients with resected, stage III melanoma with BRAF V600 mutations. MethodsIn this double-blind, placebo-controlled, phase 3 trial, we randomly assigned 870 patients with completely resected, stage III melanoma with BRAF V600E or V600K mutations to receive oral dabrafenib at a dose of 150 mg twice daily plus trametinib at a dose of 2 mg once daily (combination therapy, 438 patients) or two matched placebo tablets (432 patients) for 12 months. The primary end point was relapse-free survival. Secondary end points included overall survival, distant metastasis–free survival, freedom from relapse, and safety. ResultsAt a median follow-up of 2.8 years, the estimated 3-year rate of relapse-free survival was 58% in the combination-therapy group a...
1,017 citations
TL;DR: This article reviews biotechnological production of butanol by clostridia and some relevant fermentation and downstream processes and the strategies for strain improvement by metabolic engineering and further requirements to make fermentative butanol production a successful industrial process.
Abstract: Butanol is an aliphatic saturated alcohol having the molecular formula of C4H9OH Butanol can be used as an intermediate in chemical synthesis and as a solvent for a wide variety of chemical and textile industry applications Moreover, butanol has been considered as a potential fuel or fuel additive Biological production of butanol (with acetone and ethanol) was one of the largest industrial fermentation processes early in the 20th century However, fermentative production of butanol had lost its competitiveness by 1960s due to increasing substrate costs and the advent of more efficient petrochemical processes Recently, increasing demand for the use of renewable resources as feedstock for the production of chemicals combined with advances in biotechnology through omics, systems biology, metabolic engineering and innovative process developments is generating a renewed interest in fermentative butanol production This article reviews biotechnological production of butanol by clostridia and some relevant fermentation and downstream processes The strategies for strain improvement by metabolic engineering and further requirements to make fermentative butanol production a successful industrial process are also discussed Biotechnol Bioeng 2008;101: 209-228 © 2008 Wiley Periodicals, Inc
1,017 citations
Virginia Tech1, Lawrence Berkeley National Laboratory2, Joint Genome Institute3, Wageningen University and Research Centre4, University of Warwick5, Imperial College London6, University of California, Berkeley7, Cornell University8, Ohio Agricultural Research and Development Center9, Agriculture and Agri-Food Canada10, Agricultural Research Service11, Lawrence Livermore National Laboratory12, North Carolina State University13, University of Tennessee14, Oak Ridge National Laboratory15, University of California, Merced16, University of Queensland17, Wilkes University18, Bowling Green State University19, Hokkaido University20
TL;DR: Comparison of the two species' genomes reveals a rapid expansion and diversification of many protein families associated with plant infection such as hydrolases, ABC transporters, protein toxins, proteinase inhibitors, and, in particular, a superfamily of 700 proteins with similarity to known oömycete avirulence genes.
Abstract: Draft genome sequences have been determined for the soybean pathogen Phytophthora sojae and the sudden oak death pathogen Phytophthora ramorum. Oomycetes such as these Phytophthora species share the kingdom Stramenopila with photosynthetic algae such as diatoms, and the presence of many Phytophthora genes of probable phototroph origin supports a photosynthetic ancestry for the stramenopiles. Comparison of the two species' genomes reveals a rapid expansion and diversification of many protein families associated with plant infection such as hydrolases, ABC transporters, protein toxins, proteinase inhibitors, and, in particular, a superfamily of 700 proteins with similarity to known oomycete avirulence genes.
1,016 citations
Chang Gung University1, National Taiwan University2, Prince of Songkla University3, The Chinese University of Hong Kong4, Auckland City Hospital5, National University of Singapore6, Yonsei University7, Bombay Hospital, Indore8, University of Queensland9, Aga Khan University10, University of Malaya11, Southern Medical University12, Kaohsiung Medical University13, University of Indonesia14, University of Santo Tomas15, University of Ulsan16, University of Tokyo17
TL;DR: New HBV management guidelines include general management, indications for fibrosis assessment, time to start or stop drug therapy, choice of drug to initiate therapy, when and how to monitor the patients during and after stopping drug therapy.
Abstract: Large volume of new data on the natural history and treatment of chronic hepatitis B virus (HBV) infection have become available since 2008. These include further studies in asymptomatic subjects with chronic HBV infection and community-based cohorts, the role of HBV genotype/naturally occurring HBV mutations, the application of non-invasive assessment of hepatic fibrosis and quantitation of HBV surface antigen and new drug or new strategies towards more effective therapy. To update HBV management guidelines, relevant new data were reviewed and assessed by experts from the region, and the significance of the reported findings was discussed and debated. The earlier "Asian-Pacific consensus statement on the management of chronic hepatitis B" was revised accordingly. The key terms used in the statement were also defined. The new guidelines include general management, indications for fibrosis assessment, time to start or stop drug therapy, choice of drug to initiate therapy, when and how to monitor the patients during and after stopping drug therapy. Recommendations on the therapy of patients in special circumstances, including women in childbearing age, patients with antiviral drug resistance, concurrent viral infection, hepatic decompensation, patients receiving immune suppression or chemotherapy and patients in the setting of liver transplantation and hepatocellular carcinoma, are also included.
1,016 citations
CGIAR1, International Crops Research Institute for the Semi-Arid Tropics2, Beijing Genomics Institute3, National Research Council4, Iowa State University5, University of California, Davis6, University of Saskatchewan7, University of Córdoba (Spain)8, University of Georgia9, University of Arizona10, National Center for Genome Resources11, Commonwealth Scientific and Industrial Research Organisation12, Indian Council of Agricultural Research13, Curtin University14, University of Queensland15, Goethe University Frankfurt16, University of Western Australia17, University of Copenhagen18
TL;DR: This work reports the ∼738-Mb draft whole genome shotgun sequence of CDC Frontier, a kabuli chickpea variety, which contains an estimated 28,269 genes, and identifies targets of both breeding-associated genetic sweeps and breeding- associated balancing selection.
Abstract: Chickpea (Cicer arietinum) is the second most widely grown legume crop after soybean, accounting for a substantial proportion of human dietary nitrogen intake and playing a crucial role in food security in developing countries. We report the ~738-Mb draft whole genome shotgun sequence of CDC Frontier, a kabuli chickpea variety, which contains an estimated 28,269 genes. Resequencing and analysis of 90 cultivated and wild genotypes from ten countries identifies targets of both breeding-associated genetic sweeps and breeding-associated balancing selection. Candidate genes for disease resistance and agronomic traits are highlighted, including traits that distinguish the two main market classes of cultivated chickpea—desi and kabuli. These data comprise a resource for chickpea improvement through molecular breeding and provide insights into both genome diversity and domestication.
1,014 citations
Authors
Showing all 52145 results
| Name | H-index | Papers | Citations |
|---|---|---|---|
| Graham A. Colditz | 261 | 1542 | 256034 |
| George Davey Smith | 224 | 2540 | 248373 |
| David J. Hunter | 213 | 1836 | 207050 |
| Daniel Levy | 212 | 933 | 194778 |
| Christopher J L Murray | 209 | 754 | 310329 |
| Matthew Meyerson | 194 | 553 | 243726 |
| Luigi Ferrucci | 193 | 1601 | 181199 |
| Nicholas G. Martin | 192 | 1770 | 161952 |
| Paul M. Thompson | 183 | 2271 | 146736 |
| Jie Zhang | 178 | 4857 | 221720 |
| Alan D. Lopez | 172 | 863 | 259291 |
| Ian J. Deary | 166 | 1795 | 114161 |
| Steven N. Blair | 165 | 879 | 132929 |
| Carlos Bustamante | 161 | 770 | 106053 |
| David W. Johnson | 160 | 2714 | 140778 |